Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$825.45
4.410.54%
À la fermeture: -
$826.01
0.560.07%
Après les heures de négociation: Oct 24, 6:48 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Eli Lilly and Co a un objectif de cours consensus de $936.37, basé sur les évaluations des 28 analystes. Le plus élevé est de $1190 attribué par Citigroup le janvier 28, 2025, et le plus bas est de $610 attribué par Daiwa Capital le décembre 21, 2023. Les 3 dernières évaluations d'analystes ont été publiées par Guggenheim, Guggenheim et Morgan Stanley le octobre 16, 2025, octobre 8, 2025 et octobre 3, 2025. Avec un objectif de cours moyen de $973 entre Guggenheim, Guggenheim et Morgan Stanley, il y a une variation implicite de 17.80% upside pour Eli Lilly and Co à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Guggenheim
Morgan Stanley
Berenberg
JP Morgan
HSBC
1calculé à partir des notes des analystes
Notes d'analystes pour Eli Lilly
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/16/2025 | 14.77% | Guggenheim | $948 → $948 | Reiterates | Buy → Buy | |||
10/08/2025 | 14.77% | Guggenheim | $875 → $948 | Maintains | Buy | |||
10/03/2025 | 23.85% | Morgan Stanley | $1028 → $1023 | Maintains | Overweight | |||
09/17/2025 | 0.48% | Berenberg | $970 → $830 | Downgrade | Buy → Hold | |||
09/16/2025 | 27.12% | JP Morgan | $1100 → $1050 | Maintains | Overweight | |||
08/27/2025 | -15.26% | HSBC | $675 → $700 | Upgrade | Reduce → Hold | |||
08/13/2025 | -0.12% | Cantor Fitzgerald | $975 → $825 | Maintains | Overweight | |||
08/13/2025 | 5.93% | Guggenheim | $942 → $875 | Maintains | Buy | |||
08/11/2025 | 8.96% | Deutsche Bank | $1010 → $900 | Maintains | Buy | |||
08/08/2025 | 33.17% | JP Morgan | $1100 → $1100 | Reiterates | Overweight → Overweight | |||
08/08/2025 | 8.35% | UBS | $1050 → $895 | Maintains | Buy | |||
07/11/2025 | 14.04% | Guggenheim | $936 → $942 | Maintains | Buy | |||
07/10/2025 | 37.41% | Morgan Stanley | $1133 → $1135 | Maintains | Overweight | |||
06/20/2025 | 13.32% | Guggenheim | $936 → $936 | Reiterates | Buy → Buy | |||
05/02/2025 | 27.12% | UBS | $1100 → $1050 | Maintains | Buy | |||
04/28/2025 | -15.26% | HSBC | $1150 → $700 | Downgrade | Buy → Reduce | |||
04/22/2025 | 18.04% | Cantor Fitzgerald | → $975 | Initiates | → Overweight | |||
04/14/2025 | 12.35% | Guggenheim | $973 → $928 | Maintains | Buy | |||
04/09/2025 | 36.08% | Morgan Stanley | $1146 → $1124 | Maintains | Overweight | |||
04/08/2025 | 7.5% | Goldman Sachs | $892 → $888 | Upgrade | Neutral → Buy | |||
03/05/2025 | 33.17% | Wells Fargo | $970 → $1100 | Maintains | Overweight | |||
02/03/2025 | 25.66% | Truist Securities | $1029 → $1038 | Maintains | Buy | |||
01/28/2025 | 17.43% | Wells Fargo | $1000 → $970 | Maintains | Overweight | |||
01/28/2025 | 44.07% | Citigroup | $1250 → $1190 | Maintains | Buy | |||
12/10/2024 | 20.7% | B of A Securities | → $997 | Reinstates | → Buy | |||
11/15/2024 | 21.06% | Wolfe Research | → $1000 | Initiates | → Outperform | |||
11/04/2024 | 22.88% | Deutsche Bank | $1025 → $1015 | Maintains | Buy | |||
10/31/2024 | 24.57% | Truist Securities | $1033 → $1029 | Maintains | Buy | |||
10/31/2024 | 18.04% | Barclays | $1025 → $975 | Maintains | Overweight | |||
10/31/2024 | 33.17% | B of A Securities | $1150 → $1100 | Maintains | Buy | |||
10/25/2024 | 51.33% | Citigroup | $1060 → $1250 | Maintains | Buy | |||
10/17/2024 | 33.17% | Bernstein | — | → $1100 | Initiates | → Outperform | ||
10/10/2024 | 25.06% | Truist Securities | $1000 → $1033 | Maintains | Buy | |||
10/03/2024 | 24.09% | Deutsche Bank | $1025 → $1025 | Reiterates | Buy → Buy | |||
09/16/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
09/13/2024 | 33.17% | JP Morgan | $1050 → $1100 | Maintains | Overweight | |||
09/13/2024 | 28.33% | Citigroup | → $1060 | Reinstates | Buy → Buy | |||
09/09/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
08/27/2024 | 33.9% | Morgan Stanley | $1106 → $1106 | Reiterates | Overweight → Overweight | |||
08/19/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
08/16/2024 | 24.7% | Guggenheim | $884 → $1030 | Maintains | Buy | |||
08/14/2024 | 27.12% | Berenberg | $1000 → $1050 | Maintains | Buy | |||
08/12/2024 | 24.09% | Deutsche Bank | $725 → $1025 | Upgrade | Hold → Buy | |||
08/09/2024 | 21.06% | Wells Fargo | $875 → $1000 | Maintains | Overweight | |||
08/09/2024 | 33.29% | BMO Capital | $1001 → $1101 | Maintains | Outperform | |||
08/09/2024 | 36.2% | B of A Securities | $1000 → $1125 | Maintains | Buy | |||
08/05/2024 | 7.02% | Guggenheim | $855 → $884 | Maintains | Buy | |||
08/05/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
07/24/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
07/15/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
07/11/2024 | 21.06% | Berenberg | $850 → $1000 | Maintains | Buy | |||
07/11/2024 | 21.06% | JP Morgan | $900 → $1000 | Maintains | Overweight | |||
07/10/2024 | 24.09% | Barclays | $913 → $1025 | Maintains | Overweight | |||
07/05/2024 | 23.85% | Morgan Stanley | $1023 → $1023 | Maintains | Overweight | |||
07/03/2024 | 21.18% | BMO Capital | $1001 → $1001 | Maintains | Outperform | |||
07/01/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/26/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/25/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/25/2024 | 21.06% | Truist Securities | $892 → $1000 | Reiterates | Buy → Buy | |||
06/24/2024 | 22.88% | Jefferies | $994 → $1015 | Maintains | Buy | |||
06/24/2024 | 21.06% | B of A Securities | $1000 → $1000 | Maintains | Buy | |||
06/24/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/20/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/17/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/12/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/11/2024 | 7.14% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/07/2024 | 15.86% | Jefferies | $925 → $957 | Maintains | Buy | |||
05/14/2024 | 1.69% | Argus Research | $770 → $840 | Maintains | Buy | |||
05/01/2024 | 21.18% | BMO Capital | $900 → $1001 | Maintains | Outperform | |||
05/01/2024 | 8.96% | JP Morgan | $850 → $900 | Maintains | Overweight | |||
05/01/2024 | 7.14% | Cantor Fitzgerald | $815 → $885 | Maintains | Overweight | |||
05/01/2024 | 7.99% | Truist Securities | $850 → $892 | Maintains | Buy | |||
04/30/2024 | 7.14% | Cantor Fitzgerald | $815 → $885 | Reiterates | Overweight → Overweight | |||
04/18/2024 | -1.33% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
04/15/2024 | -1.33% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
04/11/2024 | -12.47% | Goldman Sachs | $650 → $723 | Maintains | Neutral | |||
04/05/2024 | -1.33% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
04/03/2024 | — | Erste Group | — | Upgrade | Hold → Buy | |||
04/02/2024 | 8.35% | Citigroup | $675 → $895 | Maintains | Buy | |||
04/01/2024 | -1.33% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
03/22/2024 | 2.9% | Truist Securities | → $850 | Reiterates | Buy → Buy | |||
03/15/2024 | 2.9% | JP Morgan | $775 → $850 | Maintains | Overweight | |||
03/01/2024 | 21.06% | B of A Securities | $800 → $1000 | Maintains | Buy | |||
02/21/2024 | -0.73% | DZ Bank | → $820 | Downgrade | Buy → Hold | |||
02/20/2024 | -1.33% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
02/16/2024 | 15.01% | Morgan Stanley | $805 → $950 | Maintains | Overweight | |||
02/14/2024 | -1.33% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
02/07/2024 | -1.94% | Barclays | $680 → $810 | Maintains | Overweight | |||
02/07/2024 | 2.9% | Truist Securities | $650 → $850 | Maintains | Buy | |||
02/07/2024 | -2.54% | Morgan Stanley | $763 → $805 | Maintains | Overweight | |||
02/07/2024 | -0.12% | Wells Fargo | $700 → $825 | Maintains | Overweight | |||
02/07/2024 | 4.72% | BMO Capital | $710 → $865 | Maintains | Outperform | |||
02/06/2024 | -0.12% | Wells Fargo | $700 → $825 | Maintains | Overweight | |||
02/06/2024 | -1.33% | Cantor Fitzgerald | $630 → $815 | Maintains | Overweight | |||
02/05/2024 | -23.73% | Cantor Fitzgerald | → $630 | Reiterates | Overweight → Overweight | |||
02/01/2024 | -23.73% | Cantor Fitzgerald | $630 → $630 | Reiterates | Overweight → Overweight | |||
01/24/2024 | -15.26% | Wells Fargo | $650 → $700 | Maintains | Overweight | |||
01/23/2024 | -23.73% | Cantor Fitzgerald | $630 → $630 | Reiterates | Overweight → Overweight | |||
01/23/2024 | -17.68% | Barclays | $630 → $680 | Maintains | Overweight | |||
12/21/2023 | -26.15% | Daiwa Capital | → $610 | Downgrade | Buy → Outperform |
FAQ
Quel est le cours indicatif de l'action Eli Lilly (LLY) ?
Le dernier objectif de prix pour Eli Lilly (NYSE:LLY) a été rapporté par Guggenheim le octobre 16, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $948.00 s'attendant à ce que LLY se rise dans les 12 prochains mois (un possible changement de 14.77% upside). 30 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Eli Lilly (LLY) ?
La dernière note d'analyste pour Eli Lilly (NYSE:LLY) a été fournie par Guggenheim, et Eli Lilly réitéré leur note buy.
Quand a eu lieu la dernière mise à niveau pour Eli Lilly (LLY) ?
La dernière amélioration pour Eli Lilly and Co a eu lieu le août 27, 2025 lorsque HSBC a augmenté leur objectif de prix à $700. HSBC avait précédemment a reduce pour Eli Lilly and Co.
Quand a eu lieu la dernière dégradation pour Eli Lilly (LLY) ?
La dernière réduction pour Eli Lilly and Co a eu lieu le septembre 17, 2025 lorsque Berenberg a changé leur objectif de prix de $970 à $830 pour Eli Lilly and Co.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Eli Lilly (LLY) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Eli Lilly, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Eli Lilly a été déposée le octobre 16, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 16, 2026.
La note d'analyste pour Eli Lilly (LLY) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Eli Lilly (LLY) était un réitéré avec un objectif de prix de $948.00 à $948.00. Le prix actuel de Eli Lilly (LLY) est de $826.01, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.